{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-120289","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2024-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.912167+00:00","generated_at":"2026-05-30T06:05:31.688324+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Corbus presents pre-clinical data for obesity drug CRB-913; Phase 1 start Q1 2025","bullets":["CRB-913 showed 15-fold lower brain levels vs monlunabant in mice; plasma-to-brain ratio 10x better than monlunabant.","Weight loss up to 38% in DIO mice at 80 mg/kg/day over 28 days; no plateau at doses up to 80 mg/kg/day.","Switching from semaglutide to CRB-913 maintained weight loss post-withdrawal, with doubling of fat reduction vs semaglutide alone.","Human-equivalent doses range from 30 mg/day to 450 mg/day based on allometric scaling.","IND-enabling studies ongoing; first patient in Phase 1 expected in Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-120289","json":"https://secwatch.observer/filing/0000950170-24-120289.json","markdown":"https://secwatch.observer/filing/0000950170-24-120289.md","text":"https://secwatch.observer/filing/0000950170-24-120289.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024120289/0000950170-24-120289-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024120289/crbp-20241104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T06:05:31.688324+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}